At the Endocrine Society's annual meeting in Chicago, researchers unveiled the first real-world evidence that fezolinetant, an FDA-approved nonhormone treatment, meaningfully improves the symptoms that make menopause so disruptive for millions of women—and the results match what clinicians hoped for.
Hot flashes and night sweats affect roughly 80% of menopausal women, and they're far more than a minor inconvenience. They disrupt sleep, trigger anxiety, and often coincide with depression during a life phase when women are already navigating significant physical and emotional shifts. Until recently, hormone replacement therapy was the gold standard, but many women can't or won't use it. The emergence of nonhormonal options has opened new doors, yet questions lingered about whether these medications worked as well outside of tightly controlled clinical trials.
The OPTION-VMS study, led by Pauline M. Maki, Ph.D., professor of psychiatry, psychology and OB/GYN at the University of Illinois Chicago College of Medicine, set out to answer exactly that question. Researchers followed 656 women ages 40 to 75 who had been newly prescribed nonhormonal treatments for bothersome menopausal symptoms. Among them, 201 women received fezolinetant, while 329 took SSRIs or SNRIs and 126 received other nonhormonal therapies like gabapentin or oxybutynin.
The results were striking. Women taking fezolinetant experienced significant improvements in hot flashes and night sweats within the first four weeks and sustained those gains through 12 weeks. But the medication's impact extended beyond the vasomotor symptoms it was designed to treat. Depressive and anxiety symptoms also showed substantial improvement starting at four weeks, with benefits persisting through the full 12-week observation period. The other nonhormonal treatments similarly improved mood symptoms, though the data centered on fezolinetant's comprehensive benefits.
What makes this finding particularly significant is the real-world context. Clinical trials typically enroll healthier, more carefully screened participants—people who may not reflect the broader population of women seeking help. "These findings show that in the real world, fezolinetant shows benefits similar to what was seen in clinical trials," Maki explained. "That's important because clinical trials generally have restrictive criteria for study enrollment. Study participants are generally healthier than the general population." The gap between trial results and actual clinical practice can be wide, and this evidence that fezolinetant delivers on its promise outside the lab is reassuring for both patients and physicians.
The implications reach beyond individual symptom relief. When a woman can sleep through the night, feel emotionally stable, and move through her day without the unpredictability of hot flashes, her entire quality of life shifts. The ability to work, engage with family, and maintain focus becomes possible again. For many women, the arrival of an effective nonhormonal option represents genuine agency—a chance to choose a path through menopause that aligns with their medical history and values.
As Maki noted, "The demonstration that nonhormonal treatments are effective in the real world provides women with reassurance that there are solutions for women's menopause symptoms that work and that fezolinetant, as an FDA-approved nonhormonal treatment, plays an important role." For women seeking alternatives to hormone therapy, that assurance isn't just clinical data. It's permission to expect—and demand—better.